Published in Pharmacol Res Perspect on April 07, 2014
Hedgehog signaling: modulation of cancer properies and tumor mircroenvironment. Mol Cancer (2016) 1.51
Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics. Curr Med Chem (2015) 0.77
Epigenetic polypharmacology: from combination therapy to multitargeted drugs. Clin Epigenetics (2016) 0.76
Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling. Cell Commun Signal (2017) 0.75
Hedgehog signaling in animal development: paradigms and principles. Genes Dev (2001) 14.75
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Altered neural cell fates and medulloblastoma in mouse patched mutants. Science (1997) 11.44
Patched1 regulates hedgehog signaling at the primary cilium. Science (2007) 9.21
The primary cilium: a signalling centre during vertebrate development. Nat Rev Genet (2010) 8.81
Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev (2002) 8.56
Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature (1998) 7.43
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S A (2002) 6.55
Gli2 and Gli3 localize to cilia and require the intraflagellar transport protein polaris for processing and function. PLoS Genet (2005) 6.15
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
The vertebrate primary cilium in development, homeostasis, and disease. Cell (2009) 5.29
Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development (2002) 4.80
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet (2009) 4.52
The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet (1996) 4.36
Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development (2000) 3.91
Mutations in SUFU predispose to medulloblastoma. Nat Genet (2002) 3.78
Loss of the retrograde motor for IFT disrupts localization of Smo to cilia and prevents the expression of both activator and repressor functions of Gli. Dev Biol (2005) 3.63
Tubulin modifications and their cellular functions. Curr Opin Cell Biol (2008) 3.52
Sporadic medulloblastomas contain PTCH mutations. Cancer Res (1997) 3.22
THM1 negatively modulates mouse sonic hedgehog signal transduction and affects retrograde intraflagellar transport in cilia. Nat Genet (2008) 3.19
Beta-arrestin-mediated localization of smoothened to the primary cilium. Science (2008) 3.10
Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet (2000) 2.82
Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med (2009) 2.73
Hedgehog signal transduction by Smoothened: pharmacologic evidence for a 2-step activation process. Proc Natl Acad Sci U S A (2009) 2.47
Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res (2010) 2.45
Gli1 can rescue the in vivo function of Gli2. Development (2001) 2.43
Gli2 trafficking links Hedgehog-dependent activation of Smoothened in the primary cilium to transcriptional activation in the nucleus. Proc Natl Acad Sci U S A (2009) 2.43
Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci U S A (2009) 2.41
Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol (2010) 2.25
Selective translocation of intracellular Smoothened to the primary cilium in response to Hedgehog pathway modulation. Proc Natl Acad Sci U S A (2009) 2.04
Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene (2007) 1.78
Gli proteins and the control of spinal-cord patterning. EMBO Rep (2003) 1.68
Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem (2009) 1.58
Smoothened adopts multiple active and inactive conformations capable of trafficking to the primary cilium. PLoS One (2009) 1.42
Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci U S A (2012) 1.13
Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets (2004) 1.12
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem (2010) 0.98
Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation. ACS Chem Biol (2012) 0.93